Calendar Year (CY) 2020 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule: ESRD Quality Incentive Program (ESRD QIP)

Tuesday, January 14, 2020

Presenter:
Delia Houseal, PH.D., MPH
ESRD QIP Program Lead,
Centers for Medicare & Medicaid Services (CMS)
Acronyms in this Presentation

**CDC:** Centers for Disease Control and Prevention

**CMS:** Centers for Medicare & Medicaid Services

**CY:** Calendar Year

**ECE:** Extraordinary Circumstances Exception

**ESRD:** End-Stage Renal Disease

**ESRD QIP:** End-Stage Renal Disease Quality Incentive Program

**FDA:** Food & Drug Administration

**ICH CAHPS:** In-Center Hemodialysis Consumer Assessment of Healthcare Providers and Systems

**Kt/V:** $K \text{ (dialyzer clearance of urea)} \times t \text{ (dialysis time)} / V \text{ (patient’s total body water)}$

**MAP:** Measures Application Partnership

**MedRec:** Medication Reconciliation

**mTPS:** Minimum Total Performance Score

**MIPPA:** Medicare Improvements for Patients and Providers Act of 2008

**NQF:** National Quality Form

**NHSN:** National Healthcare Safety Network

**PAMA:** Protecting Access to Medicare Act of 2014

**PPPW:** Percentage of Prevalent Patient Waitlisted

**PPS:** Prospective Payment System

**PSC:** Performance Score Certificate

**PSR:** Performance Score Report

**PY:** Payment Year

**SHR:** Standardized Hospital Ratio

**SRR:** Standardized Readmission Ratio

**STrR:** Standardized Transfusion Ratio

**SWR:** First Kidney Transplant Waitlist Ratio for Incident Dialysis Patient

**TPS:** Total Performance Score

**UFR:** Ultrafiltration Rate
Objectives

At the conclusion of today’s call, the participants will:

- Be familiar with statutory foundations
- Understand the CMS Meaningful Measures Initiative as it relates to the ESRD QIP Program
- Understand the finalized proposals for the ESRD QIP program
- Recognize the rationale for the modifications and impacts to ESRD QIP Program
- Have access to resources for the ESRD QIP Program
Today’s Call

• CMS will provide information regarding requirements for the ESRD QIP contained within the CY 2020 ESRD PPS Final Rule released on November 8, 2019.

• The information provided during this presentation is offered as an informal reference and does not constitute official CMS guidance.

• CMS encourages stakeholders, advocates, and others to refer to the Final Rule located in the Federal Register.
Statutory Foundations & Legislative Drivers
Legislative Drivers

The ESRD QIP is described in Section 1881(h) of the Social Security Act, as added by Section 153(c) of the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA).

• **Program intent:** Promote patient health by providing a financial incentive for renal dialysis facilities to deliver high-quality patient care.

• **Section 188(h):** Authorizes payment reductions of up to 2% if a facility does not meet or exceed the minimum Total Performance Score (TPS).


• ESRD QIP must include measures specific to the conditions treated with oral-only drugs, these measures are required to be outcome-based, to the extent feasible.
Statutory Overview

MIPPA requires the Health and Human Services Secretary to create an ESRD QIP that will:

- Select measures that address:
  - Anemia management
  - Dialysis adequacy
  - Patient satisfaction
  - Iron Management, bone mineral metabolism, and vascular access
- Establish performance standards
- Specify the performance period
- Develop a methodology for calculating Total Performance Scores
- Apply an appropriate payment percentage reduction
- Publicly report results
Key Initiatives
Meaningful Measures

- Promote Effective Communication & Coordination of Care
  Meaningful Measure Areas:
  - Medication Management
  - Admissions and Readmissions to Hospitals
  - Transfer of Health Information and Interoperability
- Promote Effective Prevention & Treatment of Chronic Disease
  Meaningful Measure Areas:
  - Preventive Care
  - Management of Chronic Conditions
  - Prevention, Treatment, and Management of Mental Health
  - Prevention and Treatment of Opioid and Substance Use Disorders
  - Risk Adjusted Mortality
- Work with Communities to Promote Best Practices of Healthy Living
  Meaningful Measure Areas:
  - Equity of Care
  - Community Engagement
- Make Care Affordable
  Meaningful Measure Areas:
  - Appropriate Use of Healthcare
  - Patient-focused Episode of Care
  - Risk Adjusted Total Cost of Care
- Make Care Safer by Reducing Harm Caused in the Delivery of Care
  Meaningful Measure Areas:
  - Healthcare-associated Infections
  - Preventable Healthcare Harm
- Strengthen Person & Family Engagement as Partners in their Care
  Meaningful Measure Areas:
  - Care is Personalized and Aligned with Patient’s Goals
  - End of Life Care according to Preferences
  - Patient’s Experience of Care
  - Patient Reported Functional Outcomes

Improve CMS Customer Experience
Support State Flexibility and Local Leadership
Support Innovative Approaches
Empower Patients and Doctors
The “Patients over Paperwork” Initiative was in accordance with President Trump’s Executive Order that directs federal agencies to cut the red tape.

- To reduce unnecessary regulatory burden and to allow providers to concentrate on improving patient health outcomes, CMS is:
  - Eliminating overly-burdensome regulations
  - Removing barriers to unleash innovation
  - Partnering with clinicians, providers, and administrators to ensure the focus is on the needs of the patients.

- These actions have:
  - Saved at least 5.7 billion dollars through 2021
  - Eliminated at least 40 million hours of burden through 2021
  - Removed unnecessary billing documentation requirements
Finalized Changes
PY 2022 & PY 2023 Measure Set

A facility must be eligible to receive a score on at least one measure in any two domains to receive a Total Performance Score (TPS).

**Clinical Care Domain**
40% of TPS

- Kt/V Dialysis Adequacy (comprehensive)
- VAT Measure Topic:
  - Standardized Fistula Rate
  - Long-Term Catheter Rate
- Hypercalcemia
- Standardized Transfusion Ratio (STrR)
- Ultrafiltration Rate reporting measure

**Patient & Family Engagement Domain**
15% of TPS

- ICH CAHPS

**Care Coordination Domain**
30% of TPS

- Standardized Readmission Ratio (SRR)
- Standardized Hospitalization Ratio (SHR)
- Clinical Depression Screening & Follow-Up
- Percentage of Prevalent Patients Waitlisted (PPPW)

**Safety Domain**
15% of TPS

- NHSN Bloodstream Infection (BSI)
- NHSN Dialysis Event reporting measure
- Medication Reconciliation
Summary of Proposals

- Codify program requirements in regulation text: **Finalized**
- Update the scoring methodology for the NHSN Dialysis Event reporting measure: **Finalized**
- Convert STrR clinical measure to a reporting measure: **Finalized**
- Revise the MedRec reporting measure’s scoring equation: **Not Finalized**
- Continue data validation in PY 2022 and subsequent years: **Finalized**
Updates to Regulation Text

Codify the:

• Automatic adoption of baseline and performance periods for each payment year
• Data submission requirements for all measures
• ECE process
  ▪ Including a new option to provide facilities with flexibility to reject an ECE granted by CMS
Rationale

• Finalized policies will be easier to locate
• Data submission requirements will be easier to understand
• Guidance for ECE policies will be clearer and provide additional flexibility to facilities in affected areas

• Finalized: proposed regulation text with one technical change
  - Section 413.178(d)(5) now clarifies that CMS will not consider an ECE request unless the facility making the request has complied with the requirements.
NHSN Updated Scoring Methodology

• Update scoring methodology for the NHSN Dialysis Event reporting measure
  ▪ Remove the exclusion of facilities with fewer than 12 eligible reporting months
  ▪ Assess facilities based on number of months eligible to report
  ▪ Remove the requirement that new facilities must have a CCN Open Date before October first prior to the performance period.
## Updated Scoring Distribution

### Finalized Scoring Distribution

<table>
<thead>
<tr>
<th>Percentage of Eligible Months* Reported</th>
<th>Points Awarded</th>
</tr>
</thead>
<tbody>
<tr>
<td>100% of eligible months</td>
<td>10 points</td>
</tr>
<tr>
<td>Less than 100% but no less than 50% of eligible months</td>
<td>2 points</td>
</tr>
<tr>
<td>Less than 50% of eligible months</td>
<td>0 points</td>
</tr>
</tbody>
</table>

*Eligible Months: the months in which dialysis facilities are required to report dialysis event data to NHSN per the measure eligibility criteria. Includes facilities that offer in-center hemodialysis and facilities that treat at least 11 eligible in-center hemodialysis patients during the performance period.
Rationale

• Recognize the need for adjustment:
  ▪ Effort from facilities ineligible to submit 12 months of data
    • New facilities
    • Facilities with approved ECE

• Obtain complete and accurate reporting

• Incentivize reporting for facilities eligible to report data for fewer than 12 months

• **Finalized**: Beginning with the PY 2022
STrR Clinical Measure Conversion

• Convert the STrR clinical measure into a reporting measure
• Facility must report the data required to determine the number of eligible patient-years at risk plus have a minimum of 10 patient-years at risk to receive ten points
  ▪ Multiple patients can be included within one patient year
Determining Patient-Years at Risk

1. First determine each individual patient’s time at risk (measured in days). Time at risk:
   a. Is based on CROWNWeb admit/discharge data, Medicare claims data, and other administrative data
   b. Begins at the start of the facility treatment period and continues until the earliest occurrence of one of the following:
      • It is three days prior to a transplant
      • It is the date of death
      • It is the end of facility treatment
      • It is December 31 of the year
   c. Is excluded if there is a Medicare claim within one year of their patient at-risk time for any of the following:
      • Hemolytic and aplastic anemia
      • Solid organ cancer
      • Lymphoma
      • Carcinoma in situ
      • Coagulation disorders
      • Myelodysplastic syndrome and myelofibrosis
      • Leukemia
      • Head and neck cancer
      • Metastatic Cancer
      • Sickle cell anemia
      • Multiple myeloma
Determining Patient-Years at Risk (cont.)

d. A patient is required to be on ESRD treatment for at least 90 days and to be treated to be at a facility and to be at a facility for at least 60 days before being attributed to that facility

e. A patient-month is considered eligible within two months of a month in which a patient has either of the following:
   - Nine hundred dollars of Medicare-paid dialysis claims
   - At least one Medicare inpatient claim
Determining Patient-Years at risk (cont.)

2. Next, the patient time at risk is aggregated across all patients treated at a facility during the performance year.

3. Then, it is converted into patient-years
   - Example: A facility with 4,000 days at risk during a performance year would have 10.96 patient-years at risk.
Example

CY 2020/PY 2022

Patient A
4 months

Patient B
8 months

1 full patient-year
Rationale

• Addresses concerns raised about the STrR clinical measure’s validity
• Fulfills the statutory requirement to include a measure of anemia management
• Ensures facilities are not adversely affected during examination of the measure and scoring methodology results in fair STrR measure scores
• **Finalized:** Beginning with the PY 2022
We proposed to revise the scoring equation for the MedRec reporting measure so that it accurately describes our intended policy.

- The use of facility-months was consistent with other reporting measures requiring monthly reporting.

We also clarified that facilities with a CCN Open Date before the first of October prior to the performance period must begin collecting data on that measure.
Rationale

- Recognition of alignment with NQF measure specifications
- Focus on more outcome-based measures
- Continue to calculate the measure using patient-months instead of facility-months
- **Not finalized**
NHSN Validation Study

• Becomes a permanent feature in PY 2022 and beyond and will:
  ▪ Continue using PY 2022 methodology for PY 2023 and subsequent years
  ▪ Adopt the NHSN validation study as a permanent feature of the program
Rationale

• Signals CMS’ commitment to accurate reporting of the NHSN measures
• Belief that the refinement of our methodology reflects best practices
• **Finalized:** Continuation of PY 2022 in PY 2023 and subsequent years
Updates to Regulatory Text for ESRD QIP
Performance Period: PY 2023 and Subsequent Years

The 12-month performance and baseline periods would provide sufficient and reliable quality measure data.

• Establish:
  - CY 2021 as the performance period for all measures
  - CY 2020 as the baseline period for the purposes of calculating the improvement threshold
  - CY 2019 as the baseline period for all measures for the purposes of calculating the achievement threshold, benchmark, and minimum TPS
We would automatically adopt a performance and baseline period for each year that is 1-year advanced from those specified for the previous payment year.

<table>
<thead>
<tr>
<th>PY 2024</th>
<th>CY 2022 Performance Period</th>
<th>CY 2020 Baseline Period (calculating achievement threshold, benchmark and mTPS)</th>
<th>CY 2021 Baseline Period (calculating the improvement threshold)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PY 2025</td>
<td>CY 2022 Performance Period</td>
<td>CY 2021 Baseline Period (calculating achievement threshold, benchmark and mTPS)</td>
<td>CY 2022 Baseline Period (calculating the improvement threshold)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Rationale

• Provide clear guidance to the public on policies for PY 2023 and future payment years
• Finalized
# PY 2022 Finalized Payment Reduction Scale

Using CY 2018 Data

<table>
<thead>
<tr>
<th>Total Performance Score</th>
<th>Reduction (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>100-54</td>
<td>No reduction</td>
</tr>
<tr>
<td>53-44</td>
<td>0.5% reduction</td>
</tr>
<tr>
<td>43-34</td>
<td>1.0% reduction</td>
</tr>
<tr>
<td>33-24</td>
<td>1.5% reduction</td>
</tr>
<tr>
<td>23-0</td>
<td>2.0% reduction</td>
</tr>
</tbody>
</table>
Estimated Distribution of ESRD QIP Payment Reductions

For PY 2022 and PY 2023

<table>
<thead>
<tr>
<th>Payment Reduction</th>
<th>Number of Facilities</th>
<th>Percent of Facilities*</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0%</td>
<td>5,293</td>
<td>73.88%</td>
</tr>
<tr>
<td>0.5%</td>
<td>1,339</td>
<td>18.69%</td>
</tr>
<tr>
<td>1.0%</td>
<td>432</td>
<td>6.03%</td>
</tr>
<tr>
<td>1.5%</td>
<td>81</td>
<td>1.13%</td>
</tr>
<tr>
<td>2.0%</td>
<td>19</td>
<td>0.27%</td>
</tr>
</tbody>
</table>

*223 facilities not scored due to insufficient data
## Resources

<table>
<thead>
<tr>
<th>Resource</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program (General)</td>
<td>ESRD QIP Section on CMS.gov</td>
</tr>
<tr>
<td></td>
<td>ESRD QIP Section on QualityNet</td>
</tr>
<tr>
<td>ESRD QIP Measures</td>
<td>Technical Specifications on CMS.gov</td>
</tr>
<tr>
<td></td>
<td>CMS ESRD Measures Manual on CMS.gov</td>
</tr>
<tr>
<td></td>
<td>ESRD QIP Measures on CMS.gov</td>
</tr>
<tr>
<td></td>
<td>ICH CAHPS on CMS.gov</td>
</tr>
<tr>
<td></td>
<td>ESRD QIP Measures on QualityNet</td>
</tr>
<tr>
<td>QualityNet</td>
<td>QualityNet Secure Portal</td>
</tr>
<tr>
<td>Public Reporting</td>
<td>Dialysis Facility Compare</td>
</tr>
<tr>
<td>Stakeholder Partners</td>
<td>Partners in ESRD Care</td>
</tr>
<tr>
<td>Final Rule</td>
<td>Federal Register</td>
</tr>
</tbody>
</table>

To reach us for comment: Contact vis the [ESRD QIP Q&A Tool](#) or at [ESRDQIP@CMS.HHS.gov](#)
Question & Answer Session
Thank You – Please Evaluate Your Experience

Share your thoughts to help us improve – Evaluate today’s event

Visit:

- MLN Events webpage for more information on our conference call and webcast presentations
- Medicare Learning Network homepage for other free educational materials for health care professionals

The Medicare Learning Network® and MLN Connects® are registered trademarks of the U.S. Department of Health and Human Services (HHS).
Disclaimer

This presentation was current at the time it was published or uploaded onto the web. Medicare policy changes frequently so links to the source documents have been provided within the document for your reference.

This presentation was prepared as a service to the public and is not intended to grant rights or impose obligations. This presentation may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations, and other interpretive materials for a full and accurate statement of their contents.